Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

Background: Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown. Methods: A study of endobronchial biopsy samples was conducted as part of...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 2002-09, Vol.57 (9), p.799-803
Main Authors: Gizycki, M J, Hattotuwa, K L, Barnes, N, Jeffery, P K
Format: Article
Language:English
Subjects:
Aged
Androstadienes - therapeutic use
Apoptosis
Asthma
Biological and medical sciences
Biopsy
Biopsy - methods
Bronchi - drug effects
Bronchi - ultrastructure
Bronchitis - drug therapy
Bronchitis - pathology
Bronchodilator Agents - therapeutic use
Chronic obstructive pulmonary disease
Double-Blind Method
Drug dosages
Drug therapy
Female
Fluticasone
Forced Expiratory Volume - physiology
Humans
Inflammation
Long term
Lung diseases, Obstructive
Male
Medical sciences
Microscopy
Mortality
Neutrophils
Original
Pharmacology. Drug treatments
Physiological aspects
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - pathology
Pulmonary Disease, Chronic Obstructive - physiopathology
Respiratory system
Studies
Vital Capacity - physiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown. Methods: A study of endobronchial biopsy samples was conducted as part of a double blind, placebo controlled, randomised trial of parallel design. Patients had mild to moderately severe COPD (FEV1 25–80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 μg twice daily, n=14) or placebo (n=10). Biopsy tissue taken at baseline and after treatment was examined by transmission electron microscopy to count the numbers of all ultrastructurally distinct inflammatory cells. Results: Compared with their baseline values, FP resulted in a significant decrease (on average 65%) in the numbers of mucosal mast cells (median 7.8 (range 1–33) v 2.8 (1–14), p
ISSN:0040-6376
1468-3296
DOI:10.1136/thorax.57.9.799